These data are line with a previous study, which described antibodies reacting with KIR2DL1 or KIR2DL3-receptors in 7 of 30 (23.3%) SLE patients by probing SLE sera for reactivity to E. coli-derived recombinant KIR2DL1 and KIR2DL3 in Western blot (35). Here, KIR2DL1 is linked to systemic lupus erythematosus.